Back to results
US 2023/0142244 A1Published application
Compounds and combinations thereof for treating neurological and psychiatric conditions
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Claims18
A method of treating depression comprising:
- orally administering a dosage form to a human being in need thereof for at least 8 consecutive days, wherein the dosage form comprises a dextromethorphan and a fluoxetine, wherein the human being receives a total daily dose of about 30 mg to about 150 mg of the dextromethorphan;
- wherein the dextromethorphan and the fluoxetine are the only therapeutically active agents in the dosage form;
- wherein the human being is an extensive metabolizer of dextromethorphan;
- wherein on day 8, the human being has a dextromethorphan/dextrorphan plasma ratio of 0.3 or greater three hours after the dosage form is administered.
1 more element
Dependencies are inferred from the claim text.